Error message
You must have JavaScript and cookies enabled in your browser to flag content.
Dr. Richard L. Schilsky describes ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study and similar independent studies worldwide.
Only 11% of randomized trials give enough detail to practically use in clinical practice. Here are five ways we can use internet-based communication to make it easier for academic innovators to get credit for...
A journal that aims to be the voice of global oncology has to publish work relating not only to differences in cancer biology due to risk factors, pathogenesis, and pharmacology, but also disparities arising...
More than 100 oncology practices have signed up to participate in ASCO's big data initiative. "We need good data, and lots of it, if we’re to draw meaningful conclusions that can improve patient care," writes...
We have a responsibility to design clinical trials that reflect our patient mix, and to offer hope to all of our patients rather than a select few.
I applaud the Foundation for Women’s Cancers for highlighting the importance of trials, and join them in their push for more trial options for not only my own patients, but for all patients with cancer.
The program is now available for this year's Research Community Forum Annual Meeting. Dr. Richard L. Schilsky invites you to join this unique event on September 24-25 in Alexandria, VA.
Pages